Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia

CNS Neurol Disord Drug Targets. 2022;21(10):1017-1026. doi: 10.2174/1871527321666220111124928.

Abstract

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) represents a public health problem worldwide. COVID-19 triggers a maladaptive cytokine release commonly referred to as cytokine storm syndrome with increased production of proinflammatory cytokines, which also appears to contribute to chronic neuroinflammation and neurodegenerative disorders' appearance, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. In this context, SARS-CoV-2 might enter the central nervous system through binding with the angiotensin converting enzyme 2 receptors which are highly expressed in glial cells and neurons. For this reason, an association between COVID-19, its dependent cytokine storm, and the development and/or progression of neurodegenerative disorders might be evaluated. Therefore, the aim of this review was to assess the impact of COVID-19 on neurodegenerative disorders, focusing on the possible increased mortality risk and/or deterioration of the clinical course of pre-existing chronic neurological diseases in patients with dementia.

Keywords: COVID-19; alzheimer’s disease; dementia; multiple sclerosis; neurological disorders; parkinson’s disease.

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • Cytokine Release Syndrome
  • Cytokines / metabolism
  • Dementia* / epidemiology
  • Humans
  • Neurodegenerative Diseases* / complications
  • Neurodegenerative Diseases* / epidemiology
  • Pandemics
  • SARS-CoV-2

Substances

  • Cytokines